Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: Effects on markers of inflammation and innate immunity in cervicovaginal fluid

American Journal of Reproductive Immunology

Volumn 61, Issue 2, 2009, Pages 121-129

  Anderson, Deborah J ^a   Williams, D'Nyce L ^b   Ballagh, Susan A ^b   Barnhart, Kurt ^c   Creinin, Mitchell D ^d   Newman, Daniel R ^e   Bowman, Frederick P ^a   Politch, Joseph A ^a   Duerr, Ann C ^e   Jamieson, Denise J ^e  

^a BOSTON MEDICAL CENTER   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cytokines; Diaphragm; Human immunodeficiency virus; Inflammation; Innate immunity; Microbicides

Indexed keywords

ACIDFORM; CARBOPOL 974P; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LUBRICATING AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICROBICIDE; PLACEBO; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; SAFETY; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVICITIS; UTERINE CERVIX CAP; VAGINAL LAVAGE;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; BIOLOGICAL MARKERS; CONTRACEPTIVE DEVICES, FEMALE; CYTOKINES; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MIDDLE AGED; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 58249126975     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2008.00670.x     Document Type: Article

References (39)

1. Gilliam ML, Derman RJ: Barrier methods of contraception. Obstet Gynecol Clin North Am 2000; 27: 841-858.
2. Holmes KK, Levine R, Weaver M: Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82: 454-461.
3. Moench TR, Chipato T, Padian NS: Preventing disease by protecting the cervix: The unexplored promise of internal vaginal barrier devices. Aids 2001; 15: 1595-1602.
4. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, Burki Z, Stanislawski D, Czerniewski MA, Garcia P: Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 1998; 153: 481-490.
5. Pudney J, Quayle AJ, Anderson DJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73: 1253-1263.
6. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazey RS, Notermans D, Little S, Danner SA, Richman DD, Havlir D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT: Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 1353-1357.
7. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Montgomery ET, Fancher H, Cheng H, Rosenblum M, van der Laan M, Jewell N, McIntyre J: Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial. Lancet 2007; 370: 251-261.
8. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA: Whither or wither microbicides? Science 2008; 321: 532-534.
9. Roddy RE, Cordero M, Cordero C, Fortney JA: A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993; 4: 165-170.
10. Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184: 418-428.
11. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: The story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8.
12. Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, Waller DP, Anderson RA, Profy AT, Klotman ME, Keller MJ, Herold BC: ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: Optimal candidate for microbicide combinations. J Infect Dis 2006; 194: 795-803.
13. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR: Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001; 28: 417-423.
14. Amaral E, Perdigao A, Souza MH, Mauck C, Waller D, Zaneveld L, Faundes A: Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 2006; 73: 542-547.
15. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z: Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 2001; 32: 476-482.
16. Williams DL, Newman DR, Ballagh SA, Creinin MD, Barnhart K, Weiner DH, Bell AJ, Jamieson DJ: Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex Transm Dis 2007; 34: 977-984.
17. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004; 71: 761-769.
18. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6: 90.
19. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M: Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: A randomized double-blind Phase I safety study. Contraception 2006; 74: 133-140.
20. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. Aids 2007; 21: 467-476.
21. Bollen LJ, Blanchard K, Kilmarx PH, Chaikummao S, Connolly C, Wasinrapee P, Srivirojana N, Achalapong J, Tappero JW, McNicholl JM: No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial. J Acquir Immune Defic Syndr 2008; 47: 253-257.
22. Cauci S, Guaschino S, De Aloysio D, Driussi S, De Santo D, Penacchioni P, Quadrifoglio F: Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003; 9: 53-58.
23. Hedges SR, Barrientes F, Desmond RA, Schwebke JR: Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006; 193: 556-562.
24. Doh K, Barton PT, Korneeva I, Perni SC, Bongiovanni AM, Tuttle SL, Skupski DW, Witkin SS: Differential vaginal expression of interleukin-1 system cytokines in the presence of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Infect Dis Obstet Gynecol 2004; 12: 79-85.
25. Belec L, Gherardi R, Payan C, Prazuck T, Malkin JE, Tevi-Benissan C, Pillot J: Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995; 7: 568-574.
26. Moriyama A, Shimoya K, Ogata I, Kimura T, Nakamura T, Wada H, Ohashi K, Azuma C, Saji F, Murata Y: Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 1999; 5: 656-661.
27. Anderson DJ, Politch JA, Tucker LD, Fichorova R, Haimovici F, Tuomala RE, Mayer KH: Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retroviruses 1998; 14 (Suppl. 1): S43-S49.
28. Poli G, Kinter AL, Fauci AS: Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: Inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A 1994; 91: 108-112.
29. Zara F, Nappi RE, Brerra R, Migliavacca R, Maserati R, Spinillo A: Markers of local immunity in cervico-vaginal secretions of HIV infected women: Implications for HIV shedding. Sex Transm Infect 2004; 80: 108-112.
30. Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, Malamud D, Evans-Strickfaden T, Siddig A, Caliendo AM, Hart CE, Dezzutti CS: Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006; 22: 788-795.
31. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
32. Mauck CK, Baker JM, Birnkrant DB, Rowe PJ, Gabelnick HL: The use of colposcopy in assessing vaginal irritation in research. Aids 2000; 14: 2221-2227.
33. Al-Harthi L, Kovacs A, Coombs RW, Reichelderfer PS, Wright DJ, Cohen MH, Cohn J, Cu-Uvin S, Watts H, Lewis S, Beckner S, Landay A: A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. Aids 2001; 15: 1535-1543.
34. Al-Harthi L, Wright DJ, Anderson D, Cohen M, Matity Ahu D, Cohn J, Cu-Unvin S, Burns D, Reichelderfer P, Lewis S, Beckner S, Kovacs A, Landay A: The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res 2000; 20: 719-724.
35. Gargiulo AR, Fichorova RN, Politch JA, Hill JA, Anderson DJ: Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles. Fertil Steril 2004; 82 (Suppl. 3): 1226-1234.
36. Franklin RD, Kutteh WH: Characterization of immunoglobulins and cytokines in human cervical mucus: Influence of exogenous and endogenous hormones. J Reprod Immunol 1999; 42: 93-106.
37. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-464.
38. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183: 653-656.
39. Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John-Stewart GC: Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186: 1173-1176.